Participation in this study consists in responding to some questions from two questionnaires in Romanian about how participants feel about deprescribing, participants' treatment and how participants understand medical information. After that, participants will receive a brochure and watch a video with some basic information about medications and participants' involvement in treatment decisions and in the next visit for cancer treatment participants will be asked to answer questions from one of the initial questionnaire.
cancer patients in palliative treatment
ECOG 1-2
cancer patients in curative treatment
ECOG 3-4
cognitive impairment
Single group
Educational intervention by a clinical pharmacist
Other interventionAll participants will respond to two questionnaires, both validated in Romanian and some demographic information. One is the rPATD questionnaire that investigate attitudes towards deprescribing of medication and the other one is the HLS-EU-Q16 that investigates medical literacy of participants. After completion, the clinical pharmacist will give a brochure and a video about the process of deprescribing, information about the efficacy and the adverse reactions of medicines and the role of pacient in treatment decision. When participants come to another cancer treatment (after 14 , 21 or 28 days), the rPATD will be completed again.
Impact of educational intervention performed by clinical pharmacist
Participants will be asked to complete the same questionnaire before and after an educational intervention in order to assess if this kind of educational intervention is suitable for Romanian participants. Based on answers given to the same questions before and after the intervention, investigators can see if and what is changed in the perception of participants.
Attitudes towards deprescribing medications in cancer patients in palliative treatment
Using the rPATD questionnaire (revised Patients Attitudes Towards Deprescribing ), investigators assess if Romanian cancer patients are willing to have their medication deprescribed. The questionnaire has 4 factors: Burden, Appropriateness, Involvement and Concerns about Stopping. Each factor consists of 5 statements and participants are invited to respond to a 5-point Likert scale (strongly agree =5, agree =4, unsure =3, disagree =2, strongly disagree =1). Factors' scores are calculated as the average of the summed score for the five statements pertaining to each factor, with a final score per factor ranging from 1 to 5. A higher score indicates a greater perceived burden, higher concerns about stopping and greater involvement in medication related decisions. The appropriateness factor is reversed scored so that a higher score indicates a greater belief in the appropriateness of current medications
The level of health literacy
Using the questionnaire HLS-EU-Q16 investigators can asses the level of health literacy of participants. Each of the 16 items are scored on a 4-point Likert scale ranging from 1 ("very difficult") to 4 ("very easy"). For interpretation of the final score, all items of the scale are summed, giving a score ranging between 0 (no health literacy) to 16 (high health literacy). For ease of interpretability, the three levels are identified: inadequate health literacy (0-8), problematic health literacy \[9-12\], and sufficient health literacy
Demographic characteristics of the population included in this study
Investigators will be able to characterize a population of cancer patients in Romania: number of medications, number of diseases, social background (still working or retiered) , literacy (under 8 classes, 8 classes, highschool, vocational school, superior degree).
Click on the lead sponsor to view all of their trials.
